Active substance
Finasteride
- SFDA 11
- US FDA 24
- Health Canada 20
- US price lines 5
- NHS prices 1
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Allocar | 1 mg | Film-coated tablet · Oral use | 30 Blister | SAR 90.00 | Generic · Prescription | Saudi Amarox | Valid |
| Allocar | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 68.45 | Generic · Prescription | Saudi Amarox | Valid |
| FINASID 5MG FILM COATED TABLET | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 80.50 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| FINISCAR 5MG F.C. TABLETS | 5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 75.15 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Finjuve | 2.275 mg/ml | Cutaneous spray, solution · Cutaneous use | 1 Bottle | SAR 237.20 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| PROHAIR 1 mg film-coated tablet | 1 mg | Film-coated tablet · Oral use | 30 Blister | SAR 44.05 | Generic · Prescription | HAYAT PHARMACEUTICAL INDUSTRIES | Valid |
| PROPECIA | 1 mg | Film-coated tablet · Oral use | 28 Blister | SAR 110.10 | Generic · Prescription | Organon Pharma UK Limited | Valid |
| PROSCAR | 5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 75.15 | NCE · Prescription | Organon Pharma UK Limited | Valid |
| PROSNORM | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 67.85 | Generic · Prescription | HAYAT PHARMACEUTICAL INDUSTRIES | Valid |
| PROSCAR | 5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 110.15 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| PROSTID 5MG F-C TABLETS | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 67.85 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BENIGN PROSTATIC HYPERTROPHY
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PROSCAR | 5MG | tablet · oral | ORGANON | Prescription | 19 Jun 1992 |
| PROPECIA | 1MG | tablet · oral | ORGANON | Prescription | 19 Dec 1997 |
| FINASTERIDE | 1MG | tablet · oral | DR REDDYS LABS INC | Prescription | 28 Jul 2006 |
| FINASTERIDE | 5MG | tablet · oral | TEVA | Prescription | 15 Dec 2006 |
| FINASTERIDE | 5MG | tablet · oral | DR REDDYS LABS LTD | Prescription | 28 Feb 2007 |
| FINASTERIDE | 5MG | tablet · oral | AUROBINDO PHARMA | Prescription | 30 Oct 2007 |
| FINASTERIDE | 5MG | tablet · oral | ZYDUS PHARMS USA INC | Prescription | 28 Dec 2009 |
| FINASTERIDE | 5MG | tablet · oral | ACCORD HLTHCARE | Prescription | 23 Feb 2010 |
| FINASTERIDE | 5MG | tablet · oral | HETERO LABS LTD III | Prescription | 7 Jun 2010 |
| FINASTERIDE | 5MG | tablet · oral | SUN PHARM | Prescription | 16 Aug 2011 |
| FINASTERIDE | 1MG | tablet · oral | HETERO LABS LTD III | Prescription | 1 Jul 2013 |
| FINASTERIDE | 1MG | tablet · oral | SUN PHARM | Prescription | 1 Jul 2013 |
| FINASTERIDE | 1MG | tablet · oral | ACCORD HLTHCARE | Prescription | 5 Nov 2013 |
| FINASTERIDE | 1MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 5 Nov 2013 |
| FINASTERIDE | 5MG | tablet · oral | ALKEM LABS LTD | Prescription | 5 Jan 2017 |
| FINASTERIDE | 1MG | tablet · oral | ALKEM LABS LTD | Prescription | 6 Jan 2017 |
| FINASTERIDE | 5MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 19 Jun 2006 |
| FINASTERIDE | 5MG | tablet · oral | MYLAN | Discontinued | 18 Dec 2006 |
| FINASTERIDE | 5MG | tablet · oral | GEDEON RICHTER USA | Discontinued | 22 Dec 2006 |
| FINASTERIDE | 5MG | tablet · oral | ACTAVIS TOTOWA TEVA | Discontinued | 28 Mar 2007 |
| FINASTERIDE | 1MG | tablet · oral | TEVA | Discontinued | 5 Nov 2013 |
| FINASTERIDE | 1MG | tablet · oral | NATCO PHARMA | Discontinued | 5 Nov 2013 |
| FINASTERIDE | 1MG | tablet · oral | ACTAVIS TOTOWA | Discontinued | 5 Nov 2013 |
| FINASTERIDE | 1MG | tablet · oral | CIPLA | Discontinued | 20 Nov 2014 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-FINASTERIDE | 02355043 | 5 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| AURO-FINASTERIDE | 02405814 | 5 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-FINASTERIDE 1MG | 02428148 | 1 MG | TABLET · ORAL | AURO PHARMA INC |
| BIO-FINASTERIDE | 02527847 | 5 MG | TABLET · ORAL | BIOMED PHARMA |
| FINASTERIDE | 02445077 | 5 MG | TABLET · ORAL | SANIS HEALTH INC |
| FINASTERIDE | 02445085 | 1 MG | TABLET · ORAL | SANIS HEALTH INC |
| FINASTERIDE | 02447541 | 5 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| FINASTERIDE | 02447568 | 1 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| JAMP FINASTERIDE TABLETS | 02554461 | 1 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MINT-FINASTERIDE | 02389878 | 5 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-FINASTERIDE | 02537427 | 1 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NRA-FINASTERIDE | 02535637 | 5 MG | TABLET · ORAL | NORA PHARMA INC |
| PMS-FINASTERIDE | 02310112 | 5 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-FINASTERIDE | 02320169 | 1 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PRO-FINASTERIDE | 02350270 | 5 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PROPECIA | 02238213 | 1 MG | TABLET · ORAL | ORGANON CANADA INC. |
| PROSCAR | 02010909 | 5 MG | TABLET · ORAL | ORGANON CANADA INC. |
| RIVA-FINASTERIDE | 02455013 | 5 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
| SANDOZ FINASTERIDE A | 02339471 | 1 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-FINASTERIDE | 02348500 | 5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FINASTERIDE 1 MG TABLET | $0.04359 | per EA | 23 Sep 2026 |
| US NADAC | FINASTERIDE 5 MG TABLET | $0.06881 | per EA | 23 Sep 2026 |
| US NADAC | PROPECIA 1 MG TABLET | $3.9692 | per EA | 23 Sep 2026 |
| US NADAC | PROPECIA 1 MG TABLET | $3.58415 | per EA | 23 Sep 2026 |
| US NADAC | PROSCAR 5 MG TABLET | $5.7018 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Finasteride 5mg tablets | £1.00 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Mar 2026 PROSCAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 29 Apr 2024 Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are reminded to monitor patients for both psychiatric and sexual side effects. - US FDA 1 Aug 2022 PROPECIA — safety-related labeling change
Labeling sections changed: Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - MHRA 24 May 2017 Finasteride: rare reports of depression and suicidal thoughts
We have received reports of depression and, in rare cases, suicidal thoughts in men taking finasteride 1 mg (Propecia) for male pattern hair loss. Be aware that depression is also associated with finasteride 5 mg (Proscar). - MHRA 11 Dec 2014 Finasteride: potential risk of male breast cancer
Patients should be advised to promptly report to their doctor any changes in their breast tissue such as lumps, pain, or nipple discharge.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.